Zentalis Pharmaceuticals, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone fourth-quarter summary.
Business context
Zentalis is a clinical-stage oncology biopharmaceutical company with no approved products and no product-sales revenue. Its lead programs are azenosertib, an investigational WEE1 inhibitor, and ZN-d5, an investigational BCL-2 inhibitor being studied with azenosertib. The company also conducts preclinical research on protein degraders and other targets. It relies on third parties for drug manufacturing and clinical-trial execution.
Key financial results
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $189.6 million | $172.7 million |
| Total operating expenses | $299.5 million | $227.3 million |
| Operating loss | $299.5 million | $227.3 million |
| Investment and other income, net | $22.6 million | $6.0 million |
| Net loss | $292.3 million | $237.1 million |
| Net loss per share, basic and diluted | $4.47 | $4.48 |
| Cash used in operating activities | $207.8 million | $163.8 million |
As a pre-revenue development company, operating margins are not meaningfully comparable to those of a commercial business. At year-end, cash and cash equivalents were $28.0 million and available-for-sale marketable securities were $454.9 million, totaling $482.9 million. Total assets were $551.7 million, total liabilities $114.3 million, and stockholders’ equity $437.3 million. The company reported no indebtedness.
Material changes and unusual items
- Net loss increased by $55.2 million year over year, while operating expenses rose by $72.2 million. The increase included a $45.6 million Zentera in-process research and development charge related to terminating the collaboration and reacquiring Greater China rights to azenosertib, ZN-d5 and ZN-c5.
- R&D expense increased $16.9 million, including higher personnel, facilities and consulting costs. G&A expense increased $9.8 million and included a $5.0 million operating-lease and fixed-asset impairment charge related to New York space that was subleased.
- Investment and other income increased $16.6 million, primarily reflecting higher returns on invested securities. The company also recorded a $16.0 million loss on its equity-method investment in Zentera.
- Financing cash flow was $237.3 million, primarily from a June 2023 public offering that generated $235.7 million net proceeds. The company did not sell shares under its ATM program in 2023; $140.3 million remained available under the program at year-end.
- In January 2024, Zentalis licensed its preclinical ROR1 antibody-drug conjugate and ADC platform to Immunome. It received $35 million in cash and Immunome common stock and may receive up to $275 million in milestones plus mid-to-high-single-digit royalties.
Liquidity, outlook and key risks
Management estimates existing cash, cash equivalents and marketable securities will fund operating expenses and capital expenditure requirements into 2026. This is based on assumptions that may prove inaccurate; management states the resources are not expected to fund all activities needed to complete development. Zentalis has no committed external funding source and expects to need additional capital. Further financing could dilute shareholders or require debt, partnerships, licensing or reduced development plans.
Management expects substantial ongoing costs and operating losses; profitability depends on successful clinical development, regulatory approval and commercialization, none of which is assured. Key risks include clinical-trial safety or efficacy outcomes, enrollment and execution delays, biomarker and diagnostic development, regulatory uncertainty, competition, intellectual-property protection, dependence on CROs and manufacturers, and supply-chain exposure, including third-party manufacturing in China. The company also reports that some cash deposits exceed insured limits.
Development outlook stated in the filing: topline data were expected from MAMMOTH in the second half of 2024 and DENALI in the first half of 2025; TETON topline data were expected in the second half of 2025. The company targeted its first azenosertib NDA submission in a gynecologic malignancy in 2026. These are forward-looking targets, not assured outcomes. Azenosertib has FDA Fast Track designation for a USC population; azenosertib in osteosarcoma has orphan-drug and rare-pediatric-disease designations.
Reported clinical findings include early activity and tolerability signals, but the filing cautions that preliminary and interim clinical data may change as follow-up, verification and analysis continue. The auditor issued an unqualified opinion on the financial statements and internal control over financial reporting; management also assessed those controls as effective at year-end.
Important facts for investors to verify
- Whether the stated cash runway into 2026 remains valid as trial costs, enrollment, and development plans evolve, and what financing may be required.
- Final, audited clinical results and safety data for azenosertib, including whether the DENALI and TETON studies can support the planned regulatory strategy and timeline.
- Progress and data from ZN-d5 combination development, including whether trial outcomes justify continued investment.
- The accounting and cash-flow implications of the Zentera termination, and the timing and conditions attached to Immunome milestones and royalties.
- Potential dilution from equity compensation or future financing, and the company’s ability to maintain manufacturing and clinical-trial supply.